2023

1. A Randomized Trial of Dolutegravir Plus Darunavir/ Cobicistat as a Switch Strategy in HIV-1-Infected Patients With Resistance to at Least 2 Antiretroviral Classes

   Open Forum Infectious Diseases, Vol. 10, Núm. 11

2. Peripheral modulation of antidepressant targets MAO-B and GABAAR by harmol induces mitohormesis and delays aging in preclinical models

   Nature Communications, Vol. 14, Núm. 1